Japanese Journal of Clinical Oncology Advance Access originally published online on June 23, 2005
Japanese Journal of Clinical Oncology 2005 35(7):380-385; doi:10.1093/jjco/hyi107
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Foundation for Promotion of Cancer Research
Docetaxel + 5-Fluorouracil + Cisplatin 3-day Combination Chemotherapy as a First-line Treatment in Patients with Unresectable Gastric Cancer
Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
For reprints and all correspondence: Dae Seog Heo, Department of Internal Medicine, Seoul National University College of Medicine, 28 Youngon-dong, Chongno-gu, Seoul, 110-744, Korea. E-mail: heo1013{at}plaza.snu.ac.kr
Received March 8, 2005; accepted May 8, 2005
Background: Our objective was to verify the efficacy and safety of ‘docetaxel + 5-fluorouracil + cisplatin’ 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer.
Methods: Between January and November 2002, we enrolled 43 patients [males 31; median age 55 years (range 24–74)] with inoperable gastric cancer who had not been seen previously in Seoul National University Hospital. The regimen used was docetaxel 70 mg/m2 on day 1, cisplatin 40 mg/m2 on days 2 and 3, and 5-fluorouracil 1200 mg/m2 over 10 h on days 1–3, every 3 weeks.
Results: A total of 168 cycles were administered. Mean cycle number per patient was 3.9. The administered dose intensity of docetaxel was 21.23 mg/m2/week, 5-FU 1092.14 mg/m2/week and cisplatin 23.82 mg/m2/week, which corresponded to 91.1, 91.0 and 89.5% of planned doses. Of the 43 patients, response evaluation was possible in 40 and, of these patients, 17 (42.5%) achieved a partial response, 13 (32.5%) stable disease, and 10 patients (25%) showed progressive disease. The median time to progression was 5.6 months [95% confidence interval (CI) 4.6–6.6 months]. Median overall survival was 9.0 months. (95% CI 4.8–13.2 months). Leukopenia occurred during 21.4% of cycles (36 of 168 cycles); 14.3% grade 1, 5.3% grade 2 and 1.8% grade 3. Anemia occurred in 16.7% (28 of 168 cycles); 11.3% grade 1, 4.8% grade 2 and 0.6% grade 3. Thrombocytopenia was not observed. Diarrhea, stomatitis and hypersensitivity occurred in 4.7% (two out of 43 patients), respectively. Neutropenic fever occurred in two patients (4.7%) and myalgia in three (7.0%).
Conclusion: ‘Docetaxel + 5-fluorouracil + cisplatin’ 3-day combination chemotherapy is an active and tolerable regimen as a first-line treatment in patients with unresectable gastric cancer.
Key Words: cisplatin • docetaxel • 5-fluorouracil • gastric cancer • chemotherapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Dubey, P. Hutson, D. Alberti, R. Arzoomanian, K. Binger, J. Volkman, C. Feierabend, G. Wilding, and J. H Schiller Phase I study of docetaxel and topotecan in patients with advanced malignancies Journal of Oncology Pharmacy Practice, December 1, 2005; 11(4): 132 - 138. [Abstract] [PDF]
|
|